See more : PFC Device Inc. (8231.HK) Income Statement Analysis – Financial Results
Complete financial analysis of GeneDx Holdings Corp. (WGSWW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GeneDx Holdings Corp., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Graphano Energy Ltd. (GEL.V) Income Statement Analysis – Financial Results
- Nordea Invest Europe Enhanced (NDIEUENHKL1.CO) Income Statement Analysis – Financial Results
- Meyer Apparel Limited (MAL.BO) Income Statement Analysis – Financial Results
- AIA Group Limited (AAIGF) Income Statement Analysis – Financial Results
- Sun Vending Technology Public Company Limited (SVT.BK) Income Statement Analysis – Financial Results
GeneDx Holdings Corp. (WGSWW)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.genedx.com
About GeneDx Holdings Corp.
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 202.57M | 234.69M | 212.20M | 179.32M | 196.17M |
| Cost of Revenue | 141.94M | 261.44M | 228.80M | 175.30M | 113.39M |
| Gross Profit | 60.62M | -26.75M | -16.60M | 4.03M | 82.79M |
| Gross Profit Ratio | 29.93% | -11.40% | -7.82% | 2.25% | 42.20% |
| Research & Development | 58.27M | 86.20M | 105.16M | 72.70M | 34.91M |
| General & Administrative | 133.76M | 203.33M | 205.99M | 100.74M | 29.48M |
| Selling & Marketing | 60.96M | 134.91M | 112.74M | 63.18M | 39.35M |
| SG&A | 194.71M | 338.24M | 318.73M | 163.93M | 68.84M |
| Other Expenses | -28.69M | 6.31M | 5.66M | 9.40M | 9.45M |
| Operating Expenses | 224.28M | 430.76M | 429.55M | 246.02M | 113.20M |
| Cost & Expenses | 366.23M | 692.20M | 658.34M | 421.32M | 226.59M |
| Interest Income | 1.11M | 2.54M | 79.00K | 506.00K | 988.00K |
| Interest Expense | 0.00 | 3.21M | 2.84M | 2.47M | 783.00K |
| Depreciation & Amortization | 33.73M | 63.03M | 23.36M | 14.13M | 6.41M |
| EBITDA | -136.46M | -398.20M | -219.19M | -224.73M | -22.51M |
| EBITDA Ratio | -67.37% | -168.56% | -199.98% | -126.66% | -11.48% |
| Operating Income | -163.66M | -667.65M | -446.15M | -241.99M | -30.41M |
| Operating Income Ratio | -80.79% | -284.48% | -210.25% | -134.95% | -15.50% |
| Total Other Income/Expenses | -13.03M | 69.62M | 200.76M | 654.00K | 709.00K |
| Income Before Tax | -176.69M | -598.03M | -245.39M | -241.34M | -29.70M |
| Income Before Tax Ratio | -87.23% | -254.81% | -115.64% | -134.58% | -15.14% |
| Income Tax Expense | -926.00K | -49.05M | 21.57M | 5.10M | 1.29M |
| Net Income | -175.77M | -548.98M | -245.39M | -246.44M | -30.99M |
| Net Income Ratio | -86.77% | -233.91% | -115.64% | -137.43% | -15.80% |
| EPS | -7.23 | -53.63 | -74.93 | -1.58M | -4.26 |
| EPS Diluted | -7.23 | -53.63 | -74.93 | -1.58M | -4.26 |
| Weighted Avg Shares Out | 24.31M | 10.24M | 3.28M | 155.48 | 7.28M |
| Weighted Avg Shares Out (Dil) | 24.31M | 10.24M | 3.28M | 155.48 | 7.28M |
Source: https://incomestatements.info
Category: Stock Reports